Literature DB >> 19277666

IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system.

Misato Hashizume1, Naohiko Hayakawa, Miho Suzuki, Masahiko Mihara.   

Abstract

Angiogenesis in synovia is a characteristic of RA patients. We examined whether IL-6 or TNF-alpha induce tubule formation in a co-culture system of fibroblast-like synovial cells from RA patients (RA-FLS) and human umbilical vein endothelial cells (HUVEC). The effects of IL-6 and TNF-alpha on the expression of angiogenic factors in RA-FLS and HUVEC, and the proliferation of HUVEC were also studied. IL-6 + sIL-6R induced tubule formation, whereas IL-6 alone did not. IL-6/sIL-6R-induced tubule formation was completely suppressed by the addition of either anti-IL-6R or anti-VEGF antibody. TNF-alpha did not induce tubule formation. On the contrary, it decreased CD31-positive area compared with the control. IL-6 + sIL-6R augmented VEGF production in RA-FLS, whereas IL-6 alone did not. Anti-IL-6R antibody suppressed IL-6/sIL-6R-induced VEGF production, but not spontaneous VEGF production. In contrast, TNF-alpha did not induce VEGF production from RA-FLS and HUVEC. IL-6 + sIL-6R stimulation of RA-FLS strongly induced mRNA expression of VEGF, but not of other angiogenic factors, such as EGF, bFGF, TGF-beta, IL-1, TNF-alpha and IL-8. Neither IL-6 nor IL-6/sIL-6R promoted HUVEC proliferation, whereas TNF-alpha significantly inhibited VEGF-induced HUVEC proliferation. In conclusion, IL-6/sIL-6R complex showed angiogenic activity via the production of VEGF from RA-FLS, but TNF-alpha was anti-angiogenic in our experimental system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277666     DOI: 10.1007/s00296-009-0885-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis.

Authors:  J Lu; T Kasama; K Kobayashi; Y Yoda; F Shiozawa; M Hanyuda; M Negishi; H Ide; M Adachi
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

2.  A standardized approach to PCR-based semiquantitation of multiple cytokine gene transcripts from small cell samples.

Authors:  S Lagoo-Deenadayalan; A S Lagoo; W H Barber; K J Hardy
Journal:  Lymphokine Cytokine Res       Date:  1993-04

3.  Cytokine-inducible growth factor gene expression in human umbilical endothelial cells.

Authors:  Y Ko; G Totzke; I Gouni-Berthold; A Sachinidis; H Vetter
Journal:  Mol Cell Probes       Date:  1999-06       Impact factor: 2.365

4.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.

Authors:  Yoshio Kameyama; Keiko Yamashita; Kaoru Kobayashi; Masakiyo Hosokawa; Kan Chiba
Journal:  Pharmacogenet Genomics       Date:  2005-07       Impact factor: 2.089

5.  Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice.

Authors:  H Sone; Y Kawakami; M Sakauchi; Y Nakamura; A Takahashi; H Shimano; Y Okuda; T Segawa; H Suzuki; N Yamada
Journal:  Biochem Biophys Res Commun       Date:  2001-02-23       Impact factor: 3.575

6.  Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells.

Authors:  C Patterson; M A Perrella; W O Endege; M Yoshizumi; M E Lee; E Haber
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

8.  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

Authors:  Hideko Nakahara; Jian Song; Masamichi Sugimoto; Keisuke Hagihara; Tadamitsu Kishimoto; Kazuyuki Yoshizaki; Norihiro Nishimoto
Journal:  Arthritis Rheum       Date:  2003-06

9.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors:  E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-07

10.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Authors:  R A Fava; N J Olsen; G Spencer-Green; K T Yeo; T K Yeo; B Berse; R W Jackman; D R Senger; H F Dvorak; L F Brown
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  22 in total

1.  Blockade of interleukin-6 receptor enhances the anti-arthritic effect of glucocorticoids without decreasing bone mineral density in mice with collagen-induced arthritis.

Authors:  M Suzuki; H Yoshida; M Hashizume; K Tanaka; Y Matsumoto
Journal:  Clin Exp Immunol       Date:  2015-08-31       Impact factor: 4.330

2.  In vitro cytokine release profile: predictive value for metastatic potential in head and neck squamous cell carcinomas.

Authors:  Omar Shkeir; Maria Athanassiou-Papaefthymiou; Martian Lapadatescu; Petros Papagerakis; Michael J Czerwinski; Carol R Bradford; Thomas E Carey; Mark E P Prince; Gregory T Wolf; Silvana Papagerakis
Journal:  Head Neck       Date:  2013-01-16       Impact factor: 3.147

Review 3.  IL-6 in inflammation, immunity, and disease.

Authors:  Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-04       Impact factor: 10.005

4.  The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.

Authors:  Misato Hashizume; Masahiko Mihara
Journal:  Arthritis       Date:  2011-05-26

5.  Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).

Authors:  Keisuke Izumi; Yuko Kaneko; Misato Hashizume; Keiko Yoshimoto; Tsutomu Takeuchi
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

6.  Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.

Authors:  Stevan Shaw; Tim Bourne; Chris Meier; Bruce Carrington; Rich Gelinas; Alistair Henry; Andrew Popplewell; Ralph Adams; Terry Baker; Steve Rapecki; Diane Marshall; Adrian Moore; Helen Neale; Alastair Lawson
Journal:  MAbs       Date:  2014-04-02       Impact factor: 5.857

Review 7.  The future of EPAC-targeted therapies: agonism versus antagonism.

Authors:  Euan Parnell; Timothy M Palmer; Stephen J Yarwood
Journal:  Trends Pharmacol Sci       Date:  2015-03-03       Impact factor: 14.819

8.  Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT.

Authors:  Koichi Okamura; Yukio Yonemoto; Chisa Okura; Tetsuya Higuchi; Yoshito Tsushima; Kenji Takagishi
Journal:  BMC Musculoskelet Disord       Date:  2014-11-22       Impact factor: 2.362

Review 9.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

10.  Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model.

Authors:  Anika I Tsuchida; Michiel Beekhuizen; Marijn Rutgers; Gerjo J V M van Osch; Joris E J Bekkers; Arjan G J Bot; Bernd Geurts; Wouter J A Dhert; Daniel B F Saris; Laura B Creemers
Journal:  Arthritis Res Ther       Date:  2012-12-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.